Stem Cell Therapies for Cartilage Defects: A Protocol for Systematic Review and Meta-Analysis of Randomized Controlled Trials

Siddhartha Sharma¹, Ankit Dadra¹, Prasoon Kumar¹, Ashima¹, Riddhi Gohil¹, Sandeep Patel¹, Mandeep S. Dhillon².

¹Foot and Ankle Biomechanics, Experimentation and Research (FABER) Laboratory, Department of Orthopedics, Postgraduate Institute of Medical Education and Research, Chandigarh, India.

²Department of Orthopedics, Fortis Hospital, Mohali, Punjab, India.

Correspondence to: Dr. Siddhartha Sharma, Additional Professor, Department of Orthopedics, PGIMER, Chandigarh, India. 160012 Email: <u>sids82@gmail.com</u>

Sources of Funding: Supported by a research grant from the Indian Council of Medical Research (EOI-2023-000296)

Conflicts of Interest: None

Ethics Statement: Waiver of ethical clearance has been obtained for this systematic review and meta-analysis.

Abstract

Background

Cartilage defects, arising from trauma, degenerative conditions, or genetic factors, pose significant challenges in orthopedic practice due to the limited regenerative capacity of articular cartilage. Traditional treatments like physical therapy and pain management often fail to restore tissue effectively. Recently, stem cell therapy has emerged as a promising regenerative medicine approach, potentially enhancing cartilage repair and improving joint function. This review investigates the efficacy of stem cell therapy in treating cartilage defects, focusing on pain reduction, disability, safety, quality of life, and cartilage regeneration compared to conventional care.

Methods

A PRISMA compliant systematic review and meta-analysis will be conducted by searching the PubMed, Embase, Web of Science, and Cochrane CENTRAL databases. Studies evaluating adult patients with cartilage defects of any etiology treated with various stem cell therapies will be included. Randomized controlled trials (RCTs) reporting these outcomes will be included, while non-randomized trials, non-comparative studies, non-human studies, and non-English publications will be excluded. Outcome measures will include validated functional outcome scores, rates of complications and adverse effects and healing of cartilage defects. Meta-analysis will be conducted for studies with similar interventions and outcomes, using fixed or random-

effects models based on heterogeneity assessed by the I2 statistic. The quality of evidence will be assessed using GRADE criteria.

1. Introduction

Cartilage defects, resulting from trauma, degenerative conditions, or genetic predisposition, present a substantial challenge in modern orthopedic practice. The limited regenerative capacity of articular cartilage often leads to compromised joint function, chronic pain, and reduced quality of life for affected individuals. Traditional treatment approaches, such as physical therapy and pain management, aim to alleviate symptoms but often fall short in promoting true tissue restoration. In recent years, stem cell therapy has emerged as a promising avenue in regenerative medicine, offering the potential to address the underlying pathophysiology of cartilage defects. Stem cells, with their unique ability to differentiate into various cell types, hold the promise of restoring damaged cartilage and improving joint function [1]. This review explores the role of stem cell therapy in the treatment of patients with cartilage defects, examining its potential to enhance healing, reduce pain and disability, and ultimately revolutionize the management of a challenging orthopedic issue.

2. Research Question

What is the efficacy of stem cell therapy in treating patients with cartilage defects, as measured by reduction in pain, disability, safety (severe adverse events), quality of life, and cartilage regeneration, when compared to usual care/conventional care?

3. Inclusion and Exclusion Criteria:

3.1 PICO Criteria

Patients: Adult patients with cartilage defects of any etiology (traumatic, osteoarthritis or idiopathic) in any location will be included.

4

Intervention: Any type of stem cell therapy (for e.g., umbilical cord derived stem cell therapy, bone marrow derived stem cell therapy, adipocyte derived stem cell therapy, peripheral blood derived stem cell therapy, stromal vascular fraction etc.) will be included. Standalone stem cell therapies, and therapies used in combination with procedures such as microfracture will be included.

Control: Any type of control therapy reported by the study authors will be included.

Outcomes: Validated functional outcome scores (such as VAS Score, NRS Score, IKDC Score, WOMAC Score etc.), rates and types of complications and healing of cartilage defects (ICRS or MOCART staging [2]) will be evaluated.

3.2 Inclusion Criteria:

Randomized controlled trials, conducted on human subjects, evaluating the efficacy of any type of stem cell therapy or products derived from stem cells for treating cartilage defects. Studies should have reported validated functional outcome measures. There will be no restrictions on the year of publication.

3.3 Exclusion Criteria:

- Nonrandomized controlled trials.
- Non-comparative studies (e.g., case reports, case series).
- Studies not reporting validated functional outcome measures.
- Non-English studies .
- Animal studies.

4. Search Strategy:

Electronic searches will be conducted on PubMed, Embase, Web of Science and Cochrane CENTRAL databases.

Search terms will include variations of "stem cell therapy," "cartilage defects," and outcome measures (pain reduction, disability, safety, quality of life, functional assessment). Medical Subject Headings (MeSH) terms and relevant keywords will be used.

5. Study Selection:

Two independent reviewers will screen titles and abstracts based on the inclusion/exclusion criteria. The Nested Knowledge platform will be used to manage references, screen studies and extract data for qualitative and quantitative synthesis. Full texts of potentially relevant studies will be retrieved and assessed by the same reviewers. Discrepancies will be resolved through adjudication of a third reviewer.

6. Data Extraction

Data extraction will be performed independently by two reviewers using a predefined data extraction form. Extracted data will include study characteristics (author, year, design), participant characteristics, intervention details (type of stem cell therapy), outcome measures, and results.

7. Risk of Bias Assessment

The risk of bias in included studies will be assessed using the Cochrane Risk of Bias 2 tool for RCTs [3]. Two reviewers will independently assess the risk of bias, and any disagreements will be resolved through discussion.

6

8. Data Synthesis and Analysis

Meta-analysis will be conducted for studies with similar interventions and outcome measures. Heterogeneity will be assessed using the l^2 (I-squared) statistic. If l^2 is found to be less than 50%, a fixed-effects model will be used to perform meta-analysis. If l^2 is noted to be 50% or more, a random-effects model will be used. If numbers permit, subgroup analyses will be considered based on etiology of cartilage defect, route of administration of stem cell therapy and type of stem cell therapy used. The RevMan software will be used to perform meta-analyses.

9. Sensitivity Analysis and Publication Bias:

Sensitivity analysis will be performed to assess the robustness of findings by excluding studies with high risk of bias. Publication bias will be assessed visually using funnel plots and quantitatively using methods such as Egger's test.

10. Quality of Evidence:

The quality of evidence will be assessed using GRADE (Grading of Recommendations Assessment, Development and Evaluation) criteria. The strength of evidence for each outcome will be categorized as high, moderate, low, or very low.

11. Reporting

The systematic review and meta-analysis will be reported following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines.

12. Ethical Considerations

7

Ethical approval waiver will be sought for this review as it will be based on published data.

List of Abbreviations

GRADE	Grading of Recommendations Assessment, Development and
	Evaluation
ICRS	International Cartilage Regeneration Society
MOCART	Magnetic Resonance Observation of Cartilage Repair Tissue
NRS	Numerical Response Scale
PRISMA	Preferred Reporting Items for Systematic Reviews and Meta-
	Analyses
RCT	Randomized Controlled Trial
VAS	Visual Analog Scale
WOMAC Score	Western Ontario and McMaster Universities Osteoarthritis
	Index

References

- Liu Y, Shah KM, Luo J. Strategies for Articular Cartilage Repair and Regeneration. Front Bioeng Biotechnol. 2021 Dec 17;9:770655. doi: 10.3389/fbioe.2021.770655. PMID: 34976967; PMCID: PMC8719005.
- Schreiner MM, Raudner M, Marlovits S, Bohndorf K, Weber M, Zalaudek M, Röhrich S, Szomolanyi P, Filardo G, Windhager R, Trattnig S. The MOCART (Magnetic Resonance Observation of Cartilage Repair Tissue) 2.0 Knee Score and Atlas. Cartilage. 2021 Dec;13(1_suppl):571S-587S. doi: 10.1177/1947603519865308. Epub 2019 Aug 17. PMID: 31422674; PMCID: PMC8725373.
- Sterne J A C, SavoviÄ[‡] J, Page M J, Elbers R G, Blencowe N S, Boutron I et al. RoB 2: a revised tool for assessing risk of bias in randomised trials BMJ 2019; 366 :l4898 doi:10.1136/bmj.l4898
- Brozek JL, Canelo-Aybar C, Akl EA, et al. GRADE Guidelines 30: the GRADE approach to assessing the certainty of modeled evidence-An overview in the context of health decision-making. J Clin Epidemiol. 2021 Jan;129:138-150. doi: 10.1016/j.jclinepi.2020.09.018. Epub 2020 Sep 24. PMID: 32980429; PMCID: PMC8514123.
- Page M J, McKenzie J E, Bossuyt P M, Boutron I, Hoffmann T C, Mulrow C D et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews BMJ 2021; 372 :n71 doi:10.1136/bmj.n71